Following its initial investigation into the acquisition by Theramex of certain drug rights held by Viatris, the UK’s antitrust body has said the transaction: “ 5 April 2024
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at Pharm 4 April 2024
Bimzelx (bimekizumab-bkzx) has taken a step closer to US approval, with the US regulator accepting a supplemental Biologics License Application in hidradenitis 4 April 2024
Adding to recent setbacks in the development of Leqembi (lecanemab), US firm Biogen (Nasdaq: BIIB) has revealed a filing for a subcutaneous formulation will be 3 April 2024
A report released by the nonprofit group No Patient Left Behind has claimed that it has found critical flaws in a key metric used by US insurance companies and 2 April 2024
Danish pharma trade group Lif has expressed concerns over a new bill that will make it mandatory for companies to set up safety stocks of critical medicines. 2 April 2024
With new legislation on data protection in the offing, The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called on negotiators t 2 April 2024